Patents by Inventor James P. Fandl
James P. Fandl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250206829Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.Type: ApplicationFiled: November 1, 2024Publication date: June 26, 2025Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
-
Patent number: 12054751Abstract: An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.Type: GrantFiled: December 15, 2022Date of Patent: August 6, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Gang Chen, Darya Burakov, James P. Fandl
-
Publication number: 20240036043Abstract: The present disclosure relates to a method for identifying cells that express antigen-specific antibodies with a high binding affinity for a monomeric antigen. Using fluorescence activated cell sorting, cells expressing high affinity antigen-specific antibodies are selected from a population of immune cells isolated from a mammal that has been immunized with or otherwise exposed to the antigen. Nucleic acids encoding the high affinity antibodies can then be cloned into other lymphoid and non-lymphoid cells where the antibody can be expressed and from which the antibodies can be secreted.Type: ApplicationFiled: October 2, 2023Publication date: February 1, 2024Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Gang CHEN, Robert BABB, James P. FANDL
-
Publication number: 20240018553Abstract: Expression-enhancing nucleotide sequences for eukaryotic expressions systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Genomic integration sites providing enhanced expression and methods of use thereof are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.Type: ApplicationFiled: September 6, 2023Publication date: January 18, 2024Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Ying Shen, Darya Burakov, Gang Chen, James P. Fandl
-
Patent number: 11808766Abstract: The present disclosure relates to a method for identifying cells that express antigen-specific antibodies with a high binding affinity for a monomeric antigen. Using fluorescence activated cell sorting, cells expressing high affinity antigen-specific antibodies are selected from a population of immune cells isolated from a mammal that has been immunized with or otherwise exposed to the antigen. Nucleic acids encoding the high affinity antibodies can then be cloned into other lymphoid and non-lymphoid cells where the antibody can be expressed and from which the antibodies can be secreted.Type: GrantFiled: August 7, 2020Date of Patent: November 7, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Gang Chen, Robert Babb, James P. Fandl
-
Patent number: 11788102Abstract: Expression-enhancing nucleotide sequences for eukaryotic expressions systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Genomic integration sites providing enhanced expression and methods of use thereof are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.Type: GrantFiled: September 19, 2019Date of Patent: October 17, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Ying Shen, Darya Burakov, Gang Chen, James P. Fandl
-
Publication number: 20230322956Abstract: This invention relates to site-specific integration and expression of recombinant proteins in eukaryotic cells. In particular, the invention includes compositions and methods for improved expression of antibodies including bispecific antibodies in eukaryotic cells, particularly Chinese hamster (Cricetulus griseus) cell lines, by employing an expression-enhancing locus.Type: ApplicationFiled: November 10, 2022Publication date: October 12, 2023Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Robert BABB, Darya BURAKOV, Gang CHEN, James P. FANDL
-
Publication number: 20230295583Abstract: An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.Type: ApplicationFiled: December 15, 2022Publication date: September 21, 2023Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Gang Chen, Darya Burakov, James P. Fandl
-
Publication number: 20230130799Abstract: This invention relates to site-specific integration and expression of recombinant proteins in eukaryotic cells. In particular, the invention includes compositions and methods for improved expression of antigen-binding proteins including monospecific and bispecific antibodies in eukaryotic cells, particularly Chinese hamster (Cricetulus griseus) cell lines, by employing multiple expression-enhancing locus.Type: ApplicationFiled: September 28, 2022Publication date: April 27, 2023Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Robert BABB, Darya BURAKOV, Gang CHEN, James P. FANDL, Yu ZHAO
-
Publication number: 20230094591Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.Type: ApplicationFiled: May 20, 2022Publication date: March 30, 2023Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
-
Patent number: 11560550Abstract: An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.Type: GrantFiled: May 4, 2021Date of Patent: January 24, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Gang Chen, Darya Burakov, James P. Fandl
-
Patent number: 11530277Abstract: This invention relates to site-specific integration and expression of recombinant proteins in eukaryotic cells. In particular, the invention includes compositions and methods for improved expression of antibodies including bispecifc antibodies in eukaryotic cells, particularly Chinese hamster (Cricetulus griseus) cell lines, by employing an expression-enhancing locus.Type: GrantFiled: April 20, 2017Date of Patent: December 20, 2022Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Robert Babb, Darya Burakov, Gang Chen, James P. Fandl
-
Patent number: 11512144Abstract: This invention relates to site-specific integration and expression of recombinant proteins in eukaryotic cells. In particular, the invention includes compositions and methods for improved expression of antigen-binding proteins including monospecific and bispecifc antibodies in eukaryotic cells, particularly Chinese hamster (Cricetulus griseus) cell lines, by employing multiple expression-enhancing locus.Type: GrantFiled: April 20, 2017Date of Patent: November 29, 2022Assignee: Regeneran Pharmaceuticals, Inc.Inventors: Robert Babb, Darya Burakov, Gang Chen, James P. Fandl, Yu Zhao
-
Patent number: 11370843Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.Type: GrantFiled: January 28, 2020Date of Patent: June 28, 2022Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
-
Patent number: 11268109Abstract: Expression-enhancing nucleotide sequences for eukaryotic expressions systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Genomic integration sites providing enhanced expression and methods of use thereof are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.Type: GrantFiled: February 12, 2021Date of Patent: March 8, 2022Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Ying Shen, Darya Burakov, Gang Chen, James P. Fandl
-
Publication number: 20210254022Abstract: An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.Type: ApplicationFiled: May 4, 2021Publication date: August 19, 2021Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Gang Chen, Darya Burakov, James P. Fandl
-
Publication number: 20210171984Abstract: Expression-enhancing nucleotide sequences for eukaryotic expressions systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Genomic integration sites providing enhanced expression and methods of use thereof are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.Type: ApplicationFiled: February 12, 2021Publication date: June 10, 2021Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Ying Shen, Darya Burakov, Gang Chen, James P. Fandl
-
Publication number: 20210009698Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.Type: ApplicationFiled: January 28, 2020Publication date: January 14, 2021Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
-
Publication number: 20200326349Abstract: A method of detecting and isolating cells that produce a secreted protein of interest (POI), for example, an antibody, comprising: a) providing a eukaryotic cell comprising (i) a nucleic acid encoding the POI, and (ii) a nucleic acid encoding a cell surface capture molecule, which comprises a membrane anchor and is capable of binding the POI; (b) culturing the cell under conditions in which the POI and cell surface capture molecule are expressed, and a POI-cell surface capture molecule complex is formed intracellularly and displayed on the cell surface; c) detecting the surface-displayed POI by contacting the cells with a detection molecule, which binds the POI; and d) isolating cells based on the detection molecule.Type: ApplicationFiled: February 12, 2020Publication date: October 15, 2020Inventors: James P. Fandl, Gang Chen, Neil Stahl, George D. Yancopoulos
-
Patent number: 10752698Abstract: The present disclosure relates to a method for identifying cells that express antigen-specific antibodies with a high binding affinity for a monomeric antigen. Using fluorescence activated cell sorting, cells expressing high affinity antigen-specific antibodies are selected from a population of immune cells isolated from a mammal that has been immunized with or otherwise exposed to the antigen. Nucleic acids encoding the high affinity antibodies can then be cloned into other lymphoid and non-lymphoid cells where the antibody can be expressed and from which the antibodies can be secreted.Type: GrantFiled: November 13, 2015Date of Patent: August 25, 2020Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Gang Chen, Robert Babb, James P. Fandl